ELIEM THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.98 USD | +17.40% |
|
+3.38% | +47.41% |
| Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| Apr. 11 | Top Midday Gainers | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 277.8 | 97.5 | 74.45 |
| Enterprise Value (EV) 1 | 116.4 | -25.58 | -32 |
| P/E ratio | -2.46 x | -2.13 x | -2.07 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | - | - | - |
| EV / FCF | -4,599,176 x | 1,247,483 x | -9,244,691 x |
| FCF Yield | -0% | 0% | -0% |
| Price to Book | 1.64 x | 0.76 x | 0.7 x |
| Nbr of stocks (in thousands) | 26,554 | 26,568 | 27,573 |
| Reference price 2 | 10.46 | 3.670 | 2.700 |
| Announcement Date | 3/7/22 | 3/6/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -4.696 | -11.77 | -35.67 | -45.14 | -21.47 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.547 | -20.67 | -47.48 | -45.24 | -35.12 |
| Net income 1 | -6.547 | -20.67 | -47.48 | -45.24 | -35.12 |
| Net margin | - | - | - | - | - |
| EPS 2 | -4.450 | -10.49 | -4.244 | -1.720 | -1.301 |
| Free Cash Flow | - | -6.57 | -25.3 | -20.51 | 3.462 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 6/21/21 | 6/21/21 | 3/7/22 | 3/6/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -9.383 | -10.7 | -13.13 | -13.7 | -8.748 | -9.554 | -23.44 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -9.615 | -10.54 | -13.2 | -14.6 | -9.682 | -7.762 | -22.29 |
| Net income 1 | -10.94 | -10.54 | -13.2 | -14.6 | -9.682 | -7.762 | -22.29 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -0.7000 | 1.250 | -0.5000 | -0.5600 | -0.3700 | -0.2900 | -0.8400 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/7/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/6/23 | 5/11/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 21.2 | 20.5 | 161 | 123 | 106 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -6.57 | -25.3 | -20.5 | 3.46 |
| ROE (net income / shareholders' equity) | - | -96.7% | -50.2% | -30.6% | -29.7% |
| ROA (Net income/ Total Assets) | - | -32% | -22.5% | -18.3% | -10.9% |
| Assets 1 | - | 64.67 | 210.7 | 247.2 | 321.3 |
| Book Value Per Share 2 | -3.350 | -7.310 | 6.370 | 4.840 | 3.880 |
| Cash Flow per Share 2 | 12.80 | 5.990 | 1.790 | 1.640 | 3.360 |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 6/21/21 | 6/21/21 | 3/7/22 | 3/6/23 | 3/28/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +47.41% | 112M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ELYM Stock
- Financials Eliem Therapeutics, Inc.
